Generic drug cos. win trial against Wyeth over Effexor delay
Bird & Bird 2018-10-30 3:27 pm By Cat Fredenburgh | Melbourne
Please login to bookmark Close

Wyeth must pay a group of generic drug companies for the harm they suffered after the drug maker won interlocutory injunctions blocking their plans to market an extended release generic version of anti-depressant Effexor, in a ruling likely to have a chilling effect on interlocutory injunction grants in pharmaceutical patent cases.

Subscribe to Lawyerly to access this article.

Already a subscriber?
Lost your password?

For information on rights and reprints, contact subscriptions@lawyerly.com.au